Jen-Shi Chen

Jen-Shi Chen, Professor

President, Taiwan Oncology Society; Professor, Hematology/Oncology
Organization: Linkou Chang Gung Memorial Hospital and Chang Gung University
Nationality: Taiwan
Email: js1101@cgmh.org.tw; jschen1101@gmail.com
Curriculum Vitae

Brief Introduction

Dr. Chen, born in Taiwan, is a medical professional with extensive training and experience. He graduated from China Medical University in Taichung, Taiwan, and completed his residency and medical oncology training at Linkou Chang Gung Memorial Hospital (CGMH). In 1995, he enhanced his expertise through clinical training at MD Anderson Cancer Center.

He currently serves as Professor of the Department of Hematology-Oncology at Linkou CGMH and Chang Gung University. Dr. Chen has held several leadership positions, including Chairman of the Academic Committee of the Taiwan Oncology Society (2013–2015), Secretary General of the Organizing Committee of the Asian Society of Clinical Oncology (2014), and Chairman of the Medical Oncology Committee of the Taiwan Oncology Society (2015–2017). In 2023, he was appointed President of the Taiwan Oncology Society.

Dr. Chen is a member of multiple professional and cancer research organizations, including the American Society of Clinical Oncology, the European Society for Medical Oncology, the Taiwan Society of Internal Medicine, the Taiwan Cooperative Oncology Group, and the Taiwan Clinical Oncology and Taiwan Oncology Societies. His primary research interests include clinical trials for cancers of the upper gastrointestinal tract, pancreatic-biliary cancers, gastrointestinal stromal tumors (GIST), neuroendocrine tumors, and quality of life in oncology care.

He has participated in numerous international clinical studies and served as Principal Investigator (PI) for several PI-initiated studies. To date, Dr. Chen has authored over 220 peer-reviewed articles. Notably, he co-authored studies, including the Sunitinib study for pancreatic neuroendocrine tumors published in the New England Journal of Medicine (2011), the S-1 (GEST) study for pancreatic cancer in the Journal of Clinical Oncology (2013), and the Nivolumab ATTRACTION-2 study for gastric cancer in The Lancet (2017). Most recently, his contributions include the TOPAZ-1 study on first-line treatment for biliary tract cancer and the Taiwan Pancreas Society's guidelines on systemic treatment for pancreatic cancer in 2023. He is currently involved in several novel anti-cancer drugs studies.

Specialty

Education

Selected Publications

  1. Shen WC, Hou MM, Huang TL, Wang CH, Huang YM, Chen JS, Chen ML. Transdermal buprenorphine improves overall quality of life and symptom severity in cancer patients with pain. J Clin Nurs. 2023 Feb;32(3-4):539-547.
  2. Su YY, Chiang NJ, Yang YH, Yen CJ, Bai LY, Chiu CF, Chuang SC, Yang SH, Chou WC, Chen JS, Chiu TJ, Chen YY, Chan DC, Peng CM, Chiu SC, Li CP, Shan YS, Chen LT. Real-World Data Validation of NAPOLI-1 Nomogram for the Prediction of Overall Survival in Metastatic Pancreatic Cancer. Cancers (Basel). 2023 Feb 5;15(4):1008.
  3. Satake H, Lee KW, Chung HC, Lee J, Yamaguchi K, Chen JS, Yoshikawa T, Amagai K, Yeh KH, Goto M, Chao Y, Lam KO, Han SR, Shiratori S, Shah S, Shitara K. Pembrolizumab or pembrolizumab plus chemotherapy versus standard of care chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062. Jpn J Clin Oncol. 2023 Mar 7;53(3):221-229.
  4. Huang TL, Huang YM, Hou MM, Lu CH, Chao TY, Chiu TJ, Chang YS, Lin SH, Lin CH, Chen YH, Wang CH, Chen JS, Shen WC. Safety and effectiveness of transdermal buprenorphine in cancer pain: An observational study in Taiwan (SOOTHE). Asia Pac J Clin Oncol. 2023 Apr;19(2): e45-e53.
  5. Chen CH, Wen FH, Chang WC, Hsieh CH, Chou WC, Chen JS, Tang ST. Associations of prognostic-awareness-transition patterns with emotional distress and quality of life during terminally ill cancer patients' last 6 months of life. Psychooncology. 2023 May;32(5):741-750.
  6. Wen FH, Hsieh CH, Hou MM, Su PJ, Shen WC, Chou WC, Chen JS, Chang WC, Tang ST. Decisional-Regret Trajectories From End-of-Life Decision Making Through Bereavement. J Pain Symptom Manage. 2023 Jul;66(1):44-53.
  7. Wen FH, Hsieh CH, Chou WC, Su PJ, Hou MM, Shen WC, Chen JS, Chang WC, Tang ST. Factors associated with cancer patients' distinct death-preparedness states. Psychooncology. 2023 Jul;32(7):1048-1056.
  8. Yen CC, Yang YH, Ku HY, Hu HM, Lo SS, Chang HC, Chao Y, Chen JS, Wang HP, Wang TE, Bai LY, Wu MS, Yen CJ, Chen LT, Shan YS. The impact of preoperative waiting time in Stage II-III gastric or gastroesophageal junction cancer: A population-based cohort study. Cancer Med. 2023 Aug;12(16):16906-16917.
  9. Hu YC, Chen SY, Chou WC, Chen JS, Weng LC, Tsay PK, Tang WR. The early predictive value of frailty for health-related quality of life among elderly patients with cancer receiving curative chemotherapy. PLoS One. 2023 Aug 2;18(8):e0287320.
  10. Chiu YF, Liu TW, Shan YS, Chen JS, Li CP, Ho CL, Hsieh RK, Hwang TL, Chen LT, Ch'ang HJ; Taiwan Cooperative Oncology Group pancreatic cancer study group. Carbohydrate Antigen 19-9 Response to Initial Adjuvant Chemotherapy Predicts Survival and Failure Pattern of Resected Pancreatic Adenocarcinoma but Not Which Patients Are Suited for Additional Adjuvant Chemoradiation Therapy: From a Prospective Randomized Study. Int J Radiat Oncol Biol Phys. 2023 Sep 1;117(1):74-86.